Cancer Immunotherapy Explained: How It Works, Who Responds, What It Costs

For most of the last century, cancer treatment meant attacking the tumor directly — cut it out, burn it with radiation, poison it with chemotherapy. Immunotherapy works on a different premise. Instead of targeting the cancer, it targets the immune system, removing the brakes that tumors use to avoid detection or engineering immune cells to recognize cancer they previously ignored.

The results in some cancers have genuinely changed prognosis conversations, particularly in melanoma and certain lung cancers. But immunotherapy is not a universal answer, it does not work for every patient or every tumor type, and its side effects are unlike chemotherapy’s in ways that matter enormously for safety. This guide explains the main types, how doctors predict who is likely to respond, what side effects to watch for, and what treatment costs in the United States.

Key Takeaways

Immunotherapy treats the immune system rather than the tumor directly, helping the body recognize and attack cancer cells.
Checkpoint inhibitors, which block the off-switches tumors exploit, are the most widely used form and are approved across many cancer types.
CAR T-cell therapy re-engineers a patient’s own T cells and has been most successful in certain blood cancers.
Biomarker testing — including PD-L1 expression, mismatch repair status, and tumor mutational burden — helps predict who is more likely to respond.
Immunotherapy does not work for everyone; response rates vary widely by cancer type and biomarker status.
Side effects come from immune overactivation and can affect any organ, most commonly skin, bowel, thyroid, liver, and lungs.
Immune side effects can appear weeks or even months after treatment, including after treatment ends, so report new symptoms promptly.
Costs are high — often well over $100,000 per year of treatment, and considerably more for CAR T-cell therapy — though insurance, Medicare, and manufacturer assistance programs cover much of it for eligible patients.

Why the Immune System Misses Cancer

The immune system is built to distinguish self from non-self. Cancer cells are a difficult case: they arise from your own tissue, so they look mostly like self, but they carry mutations that produce abnormal proteins the immune system can, in principle, recognize.

Tumors survive by exploiting the safety mechanisms that normally prevent the immune system from attacking healthy tissue. Chief among these are immune checkpoints — molecular brakes on T cells. When a tumor displays the right protein, it effectively presses that brake, and the T cell stands down even though it has recognized a threat. Tumors also recruit suppressive cells, alter their surface proteins to become less visible, and create a local environment hostile to immune activity.

Immunotherapy attacks that evasion strategy rather than the cancer cell itself. This explains both its promise and its central risk: releasing the brakes on the immune system can allow it to attack healthy tissue too.

The Main Types of Immunotherapy

Checkpoint inhibitors

These are antibodies that block checkpoint proteins, most commonly PD-1 on T cells, PD-L1 on tumor cells, or CTLA-4. Blocking these interactions lifts the brake and allows T cells to attack. Checkpoint inhibitors are given by infusion, usually every few weeks, and are now approved in a long list of cancers including melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, certain liver cancers, Hodgkin lymphoma, and tumors with specific genetic features regardless of where they started.

What distinguishes checkpoint inhibitors clinically is the shape of the response. Many patients see no benefit at all. But among those who do respond, a meaningful subset achieve durable remissions that persist long after treatment stops — a pattern rarely seen with conventional chemotherapy in advanced disease.

CAR T-cell therapy

Chimeric antigen receptor T-cell therapy is a personalized cell product. A patient’s T cells are collected, genetically modified in a laboratory to display a receptor that recognizes a specific target on cancer cells, expanded into large numbers, and infused back. The process takes weeks and is delivered at specialized centers.

CAR T has produced remissions in patients with certain leukemias, lymphomas, and multiple myeloma who had exhausted other options. It carries distinctive risks, particularly cytokine release syndrome — a massive inflammatory reaction causing high fever and low blood pressure — and neurological effects including confusion and difficulty speaking. Both are managed in specialized inpatient settings, and patients are typically required to stay near the treating center for a period afterward.

Other approaches

Bispecific antibodies physically bridge a T cell to a cancer cell, forcing the two together so the T cell can attack.
Monoclonal antibodies target specific proteins on cancer cells, marking them for immune destruction or blocking growth signals.
Cancer vaccines train the immune system against tumor-associated targets. Preventive vaccines against cancer-causing viruses, such as HPV vaccination, have been the clearest public health success in this category.
Oncolytic virus therapy uses modified viruses that infect tumor cells and stimulate an immune response.
Cytokine therapy, an older approach using immune signaling proteins, is still used selectively.

Who Is Likely to Respond?

Predicting response is one of the most active areas of oncology research, and biomarker testing has become routine before starting checkpoint inhibitors in many cancers.

Biomarker	What it measures	Why it matters
PD-L1 expression	How much PD-L1 protein the tumor displays	Higher expression is often associated with better response, though not perfectly predictive
Mismatch repair status (MSI-H / dMMR)	Whether the tumor can repair DNA errors	Deficient tumors accumulate mutations and tend to respond well
Tumor mutational burden	Number of mutations in the tumor	More mutations generally mean more abnormal proteins for the immune system to recognize

These markers guide decisions but do not guarantee outcomes. Patients with low PD-L1 sometimes respond well, and patients with high expression sometimes do not. Ask your oncologist which biomarker testing has been done on your tumor and what the results imply for your options — it is a question that frequently opens up treatment paths patients did not know existed, including clinical trials.

Immunotherapy is also increasingly combined with other treatments: with chemotherapy, with targeted therapy, with radiation, or with a second immunotherapy agent. Combinations often improve response rates while increasing side effect risk, which is the central trade-off in these regimens. Screening remains the most powerful tool of all for catching cancer when it is most treatable, as covered in our guide to cancer prevention, screening, and risk reduction.

Side Effects Work Differently Than Chemotherapy

This section matters more than any other for patients starting treatment. Chemotherapy side effects are largely predictable in timing and pattern. Immune-related adverse events are not. They arise when the activated immune system attacks normal tissue, they can affect essentially any organ, and they can appear weeks or months into treatment — or after it has finished.

Organ affected	Symptoms to report
Skin	Rash, itching, blistering
Colon	Diarrhea, increased stool frequency, abdominal pain, blood in stool
Thyroid and hormone glands	Fatigue, weight change, feeling cold or overheated, dizziness
Liver	Yellowing of skin or eyes, dark urine, right-sided abdominal pain
Lungs	New cough, breathlessness, chest discomfort
Joints and muscles	New joint pain, swelling, weakness
Nervous system	Numbness, weakness, severe headache, confusion

The practical rule oncology teams emphasize: report new symptoms early and specifically, and always mention that you are on immunotherapy. Diarrhea that would be trivial for most people can represent immune-mediated colitis requiring urgent treatment. Because these reactions are managed with immune-suppressing medication, and because dosing and timing are entirely individual, this is never something to self-manage with over-the-counter remedies or advice from a forum.

Carry a card or wear identification stating that you are receiving immunotherapy. If you end up in an emergency department where staff do not know your treatment, that single piece of information changes how they evaluate symptoms.

What Immunotherapy Costs

Immunotherapy sits among the most expensive categories in medicine. Checkpoint inhibitor regimens commonly carry list prices well above $100,000 per year of treatment. CAR T-cell therapy carries a product price in the hundreds of thousands of dollars before accounting for hospitalization, complication management, and travel to a specialized center.

Medicare generally covers FDA-approved immunotherapy given in an outpatient setting under Part B, subject to coinsurance that supplemental coverage often absorbs.
Commercial insurance typically covers approved indications, with prior authorization required and step therapy sometimes imposed.
Off-label use is where denials most often occur, and appeals supported by your oncologist’s documentation are frequently successful.
Manufacturer patient assistance programs and independent charitable foundations reduce out-of-pocket costs for many patients — ask the oncology financial navigator, not just the front desk.
Clinical trials may cover the investigational drug itself, though routine care costs usually remain your responsibility.

Beyond the drug, budget for the surrounding costs: scans every few months, laboratory monitoring, travel and lodging for treatment at a distant center, and time away from work for you and a caregiver. Ask for an itemized estimate up front and ask specifically whether the infusion is billed as a hospital outpatient service, which is often more expensive than a freestanding clinic. If bills are already piling up, appealing charges and negotiating payment plans is standard practice — the tactics in our overview of health insurance and healthcare access apply directly.

How Immunotherapy Compares With Other Cancer Treatments

Patients often ask where immunotherapy sits relative to the treatments they already know. The clearest way to think about it is by asking what each approach targets and how quickly it works.

Treatment	What it targets	Typical response pattern
Chemotherapy	Rapidly dividing cells throughout the body	Often works quickly; benefit frequently fades as resistance develops
Targeted therapy	A specific mutation or growth pathway in the tumor	Fast response in patients with the right mutation; resistance is common
Radiation	A defined area of tissue	Local control; sometimes combined with immunotherapy
Immunotherapy	The immune system’s ability to see the tumor	Slower onset; a subset of responders see unusually durable benefit

Two consequences follow from that difference in timing. First, scans early in immunotherapy can be misleading — a tumor may appear temporarily larger because immune cells have flooded into it, a phenomenon oncologists call pseudoprogression, so treatment decisions are rarely made on a single scan. Second, immunotherapy is increasingly used earlier in the treatment sequence, including before or after surgery in some cancers, rather than being reserved as a last resort. If you were told years ago that immunotherapy was not an option for your cancer type, that information may simply be out of date; approvals in this field have expanded steadily, and it is worth asking again.

Questions to Ask Your Oncologist

What biomarker testing has been done on my tumor, and what did it show?
What is the realistic chance that this treatment shrinks or controls my cancer?
Is immunotherapy being used alone, or combined with chemotherapy or another agent, and why?
How will we know whether it is working, and when will we reassess?
Which specific symptoms should prompt me to call immediately rather than wait for my next visit?
How long is treatment expected to continue if it is working?
Are there clinical trials I would qualify for?
Who is my financial navigator, and what assistance programs apply to this drug?

Bring someone with you to these conversations. Retention of medical information drops sharply under stress, and a second set of ears catches what you will not.

Frequently Asked Questions

Is immunotherapy better than chemotherapy?

Neither is universally better. Immunotherapy has produced durable responses in cancers where chemotherapy historically offered limited benefit, but it does not work for every tumor type or every patient. Many modern regimens combine both. The right approach depends on cancer type, stage, biomarkers, and overall health.

Does immunotherapy cause hair loss?

Generally no. Hair loss is a hallmark of many chemotherapy drugs, not of checkpoint inhibitors. Immunotherapy side effects instead reflect immune activity against normal tissues, such as rash, colitis, thyroid dysfunction, or inflammation of the lungs or liver.

How long does immunotherapy treatment last?

Duration varies by cancer type and response. Checkpoint inhibitors are often given for up to about two years in advanced disease if the cancer is responding and side effects are manageable, while some patients stop earlier. CAR T-cell therapy is typically a single infusion after preparation.

Can immunotherapy cure cancer?

Some patients achieve long-lasting remissions that continue after treatment stops, which is a meaningful and historically unusual outcome in advanced cancer. Oncologists are cautious with the word cure, and results vary substantially by cancer type, stage, and individual biology.

What happens if immunotherapy does not work?

Other options usually remain, including different immunotherapy agents, combination regimens, targeted therapy, chemotherapy, radiation, or clinical trials. Ask your oncologist about next steps and trial eligibility as soon as a treatment is being reassessed rather than waiting.

Can I take supplements during immunotherapy?

Always ask your oncology team first. Some supplements interact with cancer treatment or affect immune function, and high-dose antioxidants and herbal products are common concerns. Bring the actual bottles to your appointment so the team can review exact ingredients.

The Bottom Line

Immunotherapy has genuinely shifted what is possible in several cancers by treating the immune system rather than the tumor. It is not universal, its benefit is uneven, and its side effect profile demands a different kind of vigilance than chemotherapy. The most valuable things a patient can do are simple: ask what biomarker testing showed, ask about clinical trials, connect with a financial navigator early, and report new symptoms fast and specifically — because immune side effects caught early are usually manageable, and those ignored are not.

Medical disclaimer: This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. It does not recommend any specific therapy, drug, or dose. Cancer treatment decisions must be made with a qualified oncologist who knows your full medical history.